<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042102</url>
  </required_header>
  <id_info>
    <org_study_id>GY0010</org_study_id>
    <nct_id>NCT05042102</nct_id>
  </id_info>
  <brief_title>Donepezil and Cognitive Training for Alcohol Use Disorder</brief_title>
  <official_title>The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Connecticut Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Connecticut Healthcare System</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the project is to evaluate whether donepezil + cognitive remediation therapy is&#xD;
      superior to placebo in reducing heavy drinking in patients with alcohol use disorder in a&#xD;
      double-blind, placebo-controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heavy drinking days</measure>
    <time_frame>13 weeks of active intervention</time_frame>
    <description>Heavy drinking days as measured by weekly Time Line Follow Back (TLFB)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global neurocognitive functioning</measure>
    <time_frame>At 7 weeks and at 13 weeks</time_frame>
    <description>Global neurocognitive functioning on a global index of neurocognitive function</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Donepezil + Cognitive remediation therapy (CRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil + Placebo CRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo medication + Cognitive remediation therapy (CRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo medication + Placebo CRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Donepezil + Cognitive remediation therapy (CRT)</intervention_name>
    <description>Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.</description>
    <arm_group_label>Donepezil + Cognitive remediation therapy (CRT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Donepezil + Placebo CRT</intervention_name>
    <description>Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.</description>
    <arm_group_label>Donepezil + Placebo CRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo medication + Cognitive remediation therapy (CRT)</intervention_name>
    <description>Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.</description>
    <arm_group_label>Placebo medication + Cognitive remediation therapy (CRT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo medication + Placebo CRT</intervention_name>
    <description>Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.</description>
    <arm_group_label>Placebo medication + Placebo CRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females 18-80 years of age&#xD;
&#xD;
          2. Fluency in English and a 6th grade or higher reading level&#xD;
&#xD;
          3. Meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a&#xD;
             current alcohol use disorder (subjects should have a primary alcohol use disorder&#xD;
             [AUD] diagnosis, but may have concurrent occasional use of other substances)&#xD;
&#xD;
          4. Referred for the study within 30 days of detoxification or last alcohol use according&#xD;
             to medical records&#xD;
&#xD;
          5. Willingness to attend follow-up assessments at 13 weeks&#xD;
&#xD;
          6. Willingness to submit to Breathalyzer screenings and Urine Toxicology screenings&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lifetime diagnosis of a psychotic disorder, not induced by drug use&#xD;
&#xD;
          2. Current treatment with opioids or benzodiazepines, which may affect new learning&#xD;
&#xD;
          3. Involvement in a legal case that may lead to incarceration during the study period&#xD;
&#xD;
          4. Residential plans that would interfere with participation&#xD;
&#xD;
          5. Medical illness that may significantly compromise cognition (e.g., Parkinson's,&#xD;
             Alzheimer's, Huntington's chorea, moderate or greater TBI)&#xD;
&#xD;
          6. An uncorrected sensory impairment (hearing or sight) that would seriously interfere&#xD;
             with cognitive training&#xD;
&#xD;
          7. Pre-morbid intelligence quotient (IQ) estimate below 70&#xD;
&#xD;
          8. Unstable housing or lack of commitment to staying within a geographic area that would&#xD;
             make follow-up possible&#xD;
&#xD;
          9. Unwillingness to provide contact information of someone who can help study staff&#xD;
             contact the subjects in the event that study staff are unable to maintain contact&#xD;
             directly&#xD;
&#xD;
         10. Allergy to donepezil&#xD;
&#xD;
         11. Unstable cardiovascular disease or unstable medical condition-clinically determined by&#xD;
             a physician&#xD;
&#xD;
         12. Imminent suicidal or homicidal risk&#xD;
&#xD;
         13. Pregnant or nursing women, positive pregnancy test, or inadequate birth control&#xD;
             methods in women of childbearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gihyun Yoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University, VA Connecticut Healthcare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gihyun Yoon, MD</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>7421</phone_ext>
    <email>gihyun.yoon@yale.edu</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

